The development of effective cardiovascular medications relies heavily on intricate chemical synthesis pathways. One such crucial drug is Ticagrelor, a widely used antiplatelet agent. Central to its efficient production is the availability of high-quality intermediates. This article will explore the role of 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid, identified by CAS number 376608-65-0, as a vital component in the synthesis of Ticagrelor. For pharmaceutical researchers and procurement specialists, understanding this intermediate is key to optimizing production processes and ensuring a stable supply chain from reliable sources.

Ticagrelor: A Lifesaving Antithrombotic Agent

Ticagrelor, marketed under brand names like Brilinta and Brilique, is a direct-acting P2Y12 platelet inhibitor. It is prescribed to patients with acute coronary syndrome (ACS) to prevent platelet aggregation, thereby reducing the incidence of thrombotic events like heart attacks and strokes. Its clinical significance necessitates a consistent and reliable global supply, which in turn depends on the efficient manufacturing of its constituent intermediates.

The Crucial Role of CAS 376608-65-0

CAS 376608-65-0 serves as a key intermediate in the complex, multi-step synthesis of Ticagrelor. Its specific chemical structure and purity are critical for directing subsequent reactions and ensuring the formation of the correct stereoisomers required for Ticagrelor's biological activity. The synthesis typically involves coupling this intermediate with other advanced precursors. The quality of this intermediate directly impacts:

• Reaction Yields: Higher purity and consistent quality of Ticagrelor Intermediate lead to better yields in subsequent reaction steps, reducing waste and improving overall process efficiency.
• API Purity: Impurities in the intermediate can carry through the synthesis, potentially contaminating the final API and requiring extensive purification, which adds cost and complexity.
• Cost-Effectiveness: Sourcing a high-quality intermediate at a competitive price from a reputable manufacturer is crucial for the economic viability of drug production.

Manufacturing and Sourcing Considerations

As a leading pharmaceutical intermediate supplier, we are dedicated to producing CAS 376608-65-0 that meets the rigorous demands of API synthesis. Our manufacturing processes are optimized for:

• High Purity: We ensure an assay of 98.0%~102.0%, with minimal impurities, vital for pharmaceutical applications.
• Consistent Output: Our production facilities, located in China, are designed for consistent batch-to-batch quality and reliable output, ensuring you can buy without concern for supply disruptions.
• Scalability: We can accommodate orders ranging from research quantities to bulk commercial requirements, supporting your project from early development to full-scale manufacturing.

When seeking to purchase Ticagrelor Intermediate, engaging with a trusted manufacturer like ours is paramount. We offer not only the chemical itself but also the assurance of quality, competitive pricing, and a stable supply chain. By partnering with us, you gain access to a critical component for producing life-saving medications.

We encourage researchers and procurement specialists to request a quote and learn more about how our high-purity CAS 376608-65-0 can support your synthesis needs. Trust us to be your reliable partner in advancing cardiovascular health through quality pharmaceutical intermediates.